Clinical Trial

Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder

Name: Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder — clinical trial record (NCT07330648)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CEASE-GAD

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

A placebo-controlled superiority design was used to evaluate the efficacy of 40 mg/ day of Crisugabalin capsules in the treatment of GAD.

Trial Details

NCT Number	NCT07330648
Lead Sponsor	Anhui Medical University
Conditions	Generalized Anxiety Disorder
Enrollment	216 participants
Start Date	2025-10-10
Primary Completion	2027-01-31 (estimated)
Study Completion	2027-02-28 (estimated)
Updated on ClinicalTrials.gov	2026-01-09